Immunotherapy associated Sweet syndrome in a patient with metastatic melanoma: A case report

AbstractImmunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune‐related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metastatic melanoma.